SCHEDULE: AIGH Capital Management and Orin Hirschman Disclose 4.4% Stake in IN8bio, Inc.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.4% in IN8bio, Inc.'s common stock.

Summary

• Orin Hirschman and AIGH Capital Management LLC, along with AIGH Investment Partners, L.L.C., are jointly filing this Schedule 13G Amendment No. 2.
• The reporting persons collectively beneficially own 149,895 shares of IN8bio, Inc. Common Stock.
• This ownership represents 4.4% of the total class of securities.
• Orin Hirschman holds sole voting and sole dispositive power over all 149,895 shares.
• The filing explicitly excludes warrants to purchase an additional 303,385 common shares due to beneficial ownership limitations on exercise.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of IN8bio, Inc.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership and typically carries a neutral sentiment, as it primarily provides factual information about an investor's stake without commentary on company performance or outlook.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding IN8bio, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment entity and an individual, indicating their passive investment in IN8bio, Inc., a biotechnology company. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, but non-controlling, ownership stake by an investment group and individual.

Key Dates

Keywords

IN8bio, AIGH Capital Management, Orin Hirschman, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment, Shareholder